Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612844 | 0.85 | POLB (0.73) | TSHRHPGDHSD17B10POLBALDH1A1 | |
| SCHEMBL1612584 | 0.84 | L3MBTL1 (0.79) | POLBALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL1610031 | 0.83 | POLB (1.00) | TSHRHPGDPOLBALDH1A1MAPT | |
| SCHEMBL7992707 | 0.82 | POLB (0.97) | TSHRHPGDPOLBALDH1A1MAPT | |
| SCHEMBL1493471 | 0.81 | LMNA (0.68) | TSHRHPGDNPSR1HSD17B10POLB | |
| SCHEMBL1493482 | 0.81 | USP2 (0.77) | TSHRHPGDNPSR1HSD17B10POLB | |
| SCHEMBL29473331 | 0.81 | ALDH1A1 (0.75) | TSHRHPGDNPSR1HSD17B10POLB | |
| SCHEMBL8188675 | 0.77 | ALDH1A1 (0.72) | HSD17B10POLBALDH1A1MAPTMAPK1 | |
| SCHEMBL1493449 | 0.77 | POLB (0.68) | POLBALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL1610173 | 0.77 | POLB (0.76) | TSHRHSD17B10POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | TSHR 44/4885HPGD 3219/4885NPSR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.